Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Holding MRNA?
Track your performance easily
MRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$35.80 - $170.47
Previous Close$39.56
Volume35.48M
Average Volume (3M)7.09M
Market Cap
$15.22B
Enterprise Value$9.66B
Total Cash (Recent Filing)$6.87B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Feb 20, 2025EPS Estimate
-$2.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.82
Shares Outstanding384,817,811
10 Day Avg. Volume7,253,386
30 Day Avg. Volume7,085,134
Standard Deviation0.26
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.28
Price to Sales (P/S)2.92
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit4.69
Enterprise Value/Ebitda-4.79
Forecast
1Y Price Target
$62.31Price Target Upside58.19% Upside
Rating ConsensusHold
Number of Analyst Covering19
Moderna News
PremiumMarket News
VOO ETF Update, 12/20/2024 
PremiumMarket News
SPY ETF Update, 12/19/2024 
Bulls Say, Bears Say
Bulls Say
Financial Performance3Q revenues beat expectations due to higher Spikevax sales driven by the timing of orders.
Market ShareModerna maintains a strong retail market share of 40% for Spikevax in the current season.
Regulatory AdvantageRegulatory filing for mRNA-1083 by year-end gives MRNA first mover advantage in the COVID/flu combo vaccine market.
Bears Say
Market DemandCOVID-19 booster demand has continued to wane and while the COVID-19 & flu combo could increase patient penetration, it is not expected to meaningfully move the needle for Moderna's P&L.
Profitability ConcernsStructural issues remain around real revenue growth, flu covid combo approval risk, high opex, and low visibility on any profits even by 2028.
Revenue ProjectionsUncertainty remains about future COVID and RSV vaccination trends, affecting sales projections.
---
Ownership Overview
18.61% Insiders
20.11% Mutual Funds
22.41% Other Institutional Investors
14.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $35.80 and its highest was $170.47 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Feb 20, 2025 which is in 60 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Nov 07, 2024. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$1.805 by $1.835.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -$2.78.
How many shares outstanding does Moderna have?
Moderna has 384,817,800 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of $0.03 in its last earnings report, beating expectations of -$1.805. Following the earnings report the stock price went down -2.953%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Theleme Partners Llp. It holds Moderna’s shares valued at 483M.
---
Moderna Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$62.31 (58.19% Upside)
$62.31 (58.19% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 64%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 108.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.59%
12-Months-Change
Fundamentals
Return on Equity
-17.52%
Trailing 12-Months
Asset Growth
-18.75%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in revenue growth, cost reduction, and pipeline progress. However, challenges remain in RSV sales, international market performance, and competitive pressures in the COVID vaccine market.Read More>---
MRNA Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$62.31
▲(58.19% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
32/39 ratings generated profit
1 Year Average Return
-5.53%
assigned a sell rating 19 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 82.05% of your transactions generating a profit, with an average return of -5.53% per trade.
---